Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high ‐normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database

The objective of this analysis is to determine the effect of intensive (<120 mm Hg) versus standard (<140 mm Hg) systolic blood pressure (SBP) targets on cardiovascular (CV) outcomes among SPRINT participants with low‐normal or high‐normal fasting glucose (FG). We categorized the 5425 SPRINT participants with FG <100 mg/dL into 2 groups: <85 mg/dL (low‐normal) and 85 to <100 mg/dL (high‐normal). Among participants with low‐normal glucose, there was no significant difference in the primary outcome (PO) between the 2 treatment arms (adjusted hazard ratio, HR: 1.27 (95% confidence interval [CI] 0.68‐2.37, P = .46). However, the intensive SBP target was associated with 27% lower risk for the PO compared with the standard SBP target in those with high‐normal glucose (HR 0.73, 0.57‐0.93, P = .01). Our results indicate that hypertensive patients with high‐normal FG may benefit from intensive SBP lowering, whereas benefits were inconclusive among those with low‐normal FG.
Source: The Journal of Clinical Hypertension - Category: Cardiology Authors: Tags: ORIGINAL PAPER Source Type: research